1096 related articles for article (PubMed ID: 32603972)
61. Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease.
Zhang H; Ng KP; Therriault J; Kang MS; Pascoal TA; Rosa-Neto P; Gauthier S;
Transl Neurodegener; 2018; 7():23. PubMed ID: 30311914
[TBL] [Abstract][Full Text] [Related]
62. Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer's disease: a potential early sign of AD.
Goikolea J; Gerenu G; Daniilidou M; Mangialasche F; Mecocci P; Ngandu T; Rinne J; Solomon A; Kivipelto M; Cedazo-Minguez A; Sandebring-Matton A; Maioli S
Alzheimers Res Ther; 2022 Feb; 14(1):37. PubMed ID: 35209952
[TBL] [Abstract][Full Text] [Related]
63. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease.
Sarlus H; Eyjolfsdottir H; Eriksdotter M; Oprica M; Schultzberg M
J Alzheimers Dis; 2015; 48(2):495-505. PubMed ID: 26402013
[TBL] [Abstract][Full Text] [Related]
64. Association of CSF Aβ
Cullen N; Janelidze S; Palmqvist S; Stomrud E; Mattsson-Carlgren N; Hansson O;
Neurology; 2022 Mar; 98(9):e958-e967. PubMed ID: 34937781
[TBL] [Abstract][Full Text] [Related]
65. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
[TBL] [Abstract][Full Text] [Related]
66. Associations of erythrocyte omega-3 fatty acids with cognition, brain imaging and biomarkers in the Alzheimer's disease neuroimaging initiative: cross-sectional and longitudinal retrospective analyses.
Rouch L; Virecoulon Giudici K; Cantet C; Guyonnet S; Delrieu J; Legrand P; Catheline D; Andrieu S; Weiner M; de Souto Barreto P; Vellas B;
Am J Clin Nutr; 2022 Dec; 116(6):1492-1506. PubMed ID: 36253968
[TBL] [Abstract][Full Text] [Related]
67. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
[TBL] [Abstract][Full Text] [Related]
68. Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer's Disease Progression that Reinforces the 2018 NIA-AA Research Framework.
Devanarayan P; Devanarayan V; Llano DA;
J Alzheimers Dis; 2019; 68(2):537-550. PubMed ID: 30775985
[TBL] [Abstract][Full Text] [Related]
69. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
[TBL] [Abstract][Full Text] [Related]
70. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers.
Jang H; Park J; Woo S; Kim S; Kim HJ; Na DL; Lockhart SN; Kim Y; Kim KW; Cho SH; Kim SJ; Seong JK; Seo SW;
Neuroimage Clin; 2019; 24():101941. PubMed ID: 31376643
[TBL] [Abstract][Full Text] [Related]
71. Cerebrospinal Fluid sTREM2 Has Paradoxical Association with Brain Structural Damage Rate in Early- and Late-Stage Alzheimer's Disease.
Leng F; Zhan Z; Sun Y; Liu F; Edison P; Sun Y; Wang Z;
J Alzheimers Dis; 2022; 88(1):117-126. PubMed ID: 35491791
[TBL] [Abstract][Full Text] [Related]
72. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
[TBL] [Abstract][Full Text] [Related]
73. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline.
Bucci M; Chiotis K; Nordberg A;
Mol Psychiatry; 2021 Oct; 26(10):5888-5898. PubMed ID: 34593971
[TBL] [Abstract][Full Text] [Related]
74. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
75. Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment.
Lu Y;
Aging Clin Exp Res; 2022 Oct; 34(10):2399-2406. PubMed ID: 35988117
[TBL] [Abstract][Full Text] [Related]
76. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL;
Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012
[TBL] [Abstract][Full Text] [Related]
77. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
[TBL] [Abstract][Full Text] [Related]
78. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
[TBL] [Abstract][Full Text] [Related]
79. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
80. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H;
Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
